SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · BridgeBio reported Q2 2026 total revenues of $243.7M (+120.5% YoY),…

BridgeBio Pharma, Inc. · PRESS-RELEASE filed Aug 10, 2026 at 16:01 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Aug 10, 2026 at 16:01 ET

BridgeBio reported Q2 2026 total revenues of $243.7M (+120.5% YoY), driven by $222.4M in Attruby net product revenue (+211% YoY), but GAAP EPS of $(0.78) missed consensus of $(0.64) by 22%. The company is investing heavily in three upcoming launches and closed a $1B preferred equity financing post-quarter, strengthening its balance sheet for pipeline expansion.

  • Q2 2026 total revenues $243.7M, up 120.5% YoY from $110.6M
  • Attruby net product revenue $222.4M, up 211% YoY from $71.5M
  • GAAP net loss per share $(0.78) vs consensus $(0.64), 21.9% miss
  • Three NDAs under FDA Priority Review: BBP-418 (PDUFA Nov 27, 2026), encaleret (PDUFA May 8, 2027), infigratinib (submitted)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access